Soligenix, Inc. Common Stock, also called Soligenix, is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. Read More It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ. The listed name for SNGX is Soligenix, Inc. Common Stock.